Jiangsu Recbio Technology Co., Ltd. (HKG:2179)
Hong Kong · Delayed Price · Currency is HKD 5.03
-0.01 (-0.20%)
Jul 22, 2026, 9:45 AM HKT
Jiangsu Recbio Technology Revenue
In the year 2025, Jiangsu Recbio Technology had annual revenue of 12.73M CNY. Jiangsu Recbio Technology had revenue of -7.00M in the half year ending December 31, 2025.
Revenue
12.73M CNY
Revenue Growth
n/a
P/S Ratio
219.08
Revenue / Employee
25.92K CNY
Employees
491
Market Cap
3.10B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.73M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 30.38M | 25.05M | 470.46% |
| Dec 31, 2022 | 5.33M | -874.00K | -14.10% |
| Dec 31, 2021 | 6.20M | 4.74M | 325.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 1.92B |
| Qyuns Therapeutics | 897.99M |
| Shandong Boan Biotechnology | 873.36M |
| Medtide | 634.40M |
| Mirxes Holding Company | 166.32M |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |
| Antengene Corporation | 117.22M |
| Jacobio Pharmaceuticals Group | 59.56M |